Globus Medical Reports 27% Revenue Growth to $759.9 Million in Latest Quarter

Globus Medical, Inc. reported significant financial growth in its latest quarterly results, with net sales reaching $759.9 million for the three months ended March 31, 2026, a 27% increase from $598.1 million in the same period last year. The company's net income also rose to $124.3 million, or $0.90 per diluted share, compared to $75.5 million, or $0.54 per diluted share, in the prior year. This growth was primarily driven by increased sales in both the Musculoskeletal Solutions and Enabling Technologies segments, with notable contributions from the recently acquired Nevro Corp., which generated $82.7 million in revenue during the quarter.

In terms of operational metrics, Globus Medical's U.S. sales increased by 25% to $604.9 million, bolstered by a $67.2 million contribution from Nevro and a $53.7 million rise in Musculoskeletal Solutions sales. International sales also saw a robust 35.6% increase, totaling $155 million, with significant growth in Europe and the Middle East. The company’s total assets grew to $5.44 billion, up from $5.30 billion at the end of 2025, reflecting a strong cash position of $561 million and a notable increase in accounts receivable and inventories.

Strategically, the company has been active in expanding its product offerings and market presence. The Nevro merger, completed in April 2025, has been a key driver of growth, allowing Globus to enhance its portfolio in spinal cord stimulation and neuromonitoring services. Additionally, the company has continued to invest in research and development, with expenses rising to $36.5 million, reflecting a commitment to innovation and product development. The company also reported restructuring costs of $5.2 million as part of its ongoing efforts to optimize operations and integrate Nevro's business.

Globus Medical's operational efficiency is evident in its cost management, with the cost of sales as a percentage of net sales decreasing to 30.8% from 32.7% year-over-year. The company has also maintained a strong balance sheet, with total liabilities decreasing to $707.2 million from $729.5 million, and a healthy equity position of $4.73 billion. Looking ahead, the company anticipates continued growth driven by its expanded product offerings and market penetration strategies, while also navigating potential challenges related to market conditions and competition in the medical device industry.